

AUTHOR INDEX FOR VOLUME 25

A

- Abel, Peter W.** See *Minneman*, 56
- Aguayo, L. G.**
See *El-Fakahany, Eldefrawi, Murphy, Triggle, Albuquerque, and Eldefrawi*, 369
- Akaike, Akinori**
Ikeda, Stephen R., Brookes, Neville, Pascuzzo, Gary J., Rickett, Daniel L., and Albuquerque, Edson X. The Nature of the Interactions of Pyridostygmine with the Nicotinic Acetylcholine Receptor-Ionic Channel Complex. II. Patch Clamp Studies, 102
See *Pascuzzo, Maleque, Shaw, Aronstam, Rickett, and Albuquerque*, 86
- Albuquerque, E. X.**
See *El-Fakahany, Eldefrawi, Murphy, Aguayo, Triggle, and Eldefrawi*, 369
See *Pascuzzo, Akaike, Maleque, Shaw, Aronstam, and Rickett*, 92
See *Souccar, Varanda, and Daly*, 384
See *Souccar, Varanda, Aronstam, and Daly*, 395
- Aman, Rashid A.** See *Rosenbaum, Holford, Richards, and Sadée*, 242
- Angel, Lloyd M.** See *Hiller and Simon*, 249
- Armitage, I. M.** See *Fesik, Ellestad, and McGahren*, 275, 281
- Aronstam, Robert S.**
See *Pascuzzo, Akaike, Maleque, Shaw, Rickett, and Albuquerque*, 92
See *Souccar, Varanda, Daly, and Albuquerque*, 395
- Audigier, Y.** See *Castanas, Giraud, Drissi, Boudouresque, Conte-Devolx, and Oliver*, 38

B

- Bamberger, Michelle J.** See *Oswald and McLaughlin*, 360
- Barovsky, Kenneth, Pedone, Carolyn, and Brooker, Gary.** Distinct Mechanisms of Forskolin-Stimulated Cyclic AMP Accumulation and Forskolin-Potentiated Hormone Responses in C6-2B Cells, 256
- Bartel, Ronnda L., and Borchardt, Ronald T.** Effects of Adenosine Dialdehyde on S-Adenosylhomocysteine Hydrolase and S-Adenosylmethionine-Dependent Transmethylation in Mouse L929 Cells, 418
- Bartolucci, Simonetta.** See *Momparler, Rossi, Bouchard, Vaccaro, and Momparler*, 436
- Baxter, Diane M.**
See *Harris, Groh, and Hitzemann*, 410
See *Harris, Mitchell, and Hitzemann*, 401
- Belinsky, Steven A., Matsumura, Takakatsu, Kauffman, Frederick C., and Thurman, Ronald D.** Rates of Allyl Alcohol Metabolism in Periportal and Pericentral Regions of the Liver Lobule, 158
- Benkovic, S. J.** See *Slieker*, 294
- Berger, Sondra H., and Hakala, Maire T.** Relationship of dUMP and Free FdUMP Pools to Inhibition of Thymidylate Synthase by 5-Fluorouracil, 303
- Billings, Ruth E.** Decreased Hepatic 5,10-Methylenetetrahydrofolate Reductase Activity in Mice after Chronic Phenytoin Treatment, 459
- Blisard, Karen S.** See *Starke and Mieyal*, 467
- Borchardt, Ronald T.** See *Bartel*, 418
- Bouchard, Jacques.** See *Momparler, Rossi, Vaccaro, Momparler, and Bartolucci*, 436
- Boudouresque, F.** See *Castanas, Giraud, Audigier, Drissi, Conte-Devolx, and Oliver*, 38
- Bradley, Roger D.** See *Lown, Hanstock, and Scraba*, 178
- Brattsand, Ralph.** See *Dahlberg, Thalén, Gustafsson, Johansson, Roempke, and Saartok*, 70

- Brodersen, Bent.** See *Honoré*, 137
- Brooker, Gary.** See *Barovsky and Pedone*, 256
- Brookes, Neville.** See *Akaike, Ikeda, Pascuzzo, Rickett, and Albuquerque*, 102
- Buckman, Trent D., Sutphin, Mary S., and Eiduson, Samuel.** Proteases as Probes of Mitochondrial Monoamine Oxidase Topography *in Situ*, 165
- Bull, H. G.** See *Cascieri, Mumford, Patchett, Thornberry, and Liang*, 287
- Bushfield, Mark.** See *Drummond and Macphee*, 201

C

- Cascieri, M. A., Bull, H. G., Mumford, R. A., Patchett, A. A., Thornberry, N. A., and Liang, T.** Carboxyl-Terminal Tripeptidyl Hydrolysis of Substance P by Purified Rabbit Lung Angiotensin-Converting Enzyme and the Potentiation of Substance P Activity *in Vivo* by Captopril and MK-422, 287
- Castanas, E., Giraud, P., Audigier, Y., Drissi, R., Boudouresque, F., Conte-Devolx, B., and Oliver, C.** Adrenal Medullary Opiate Receptors: Pharmacological Characterization in Bovine Adrenal Medulla and a Human Pheochromocytoma, 38
- Catterall, William A.**
See *Postma*, 219
See *Willow and Kuenzel*, 228
- Chen, Ming S., Woods, Kathleen L., and Prusoff, William H.** Molecular Basis of the Antineoplastic Activity of 3'-Amino-3'-deoxythymidine, 441
- Christie, James L.,** See *Rosen, Rauckman, Ellington, Dahlin, and Nelson*, 151
- Chuang, De-Maw.** See *Majewska*, 352
- Conn, P. Michael, Rogers, Deloris C., and Seay, Sallie G.** Biphasic Regulation of the Gonadotropin-Releasing Hormone Receptor by Microaggregation and Intracellular Ca²⁺ Levels, 51
- Coon, Minor J.** See *Koop*, 494
- Conte-Devolx, B.** See *Castanas, Giraud, Audigier, Drissi, Boudouresque, and Oliver*, 38
- Conti-Tronconi, Bianca M.** See *Saiani, Kageyama, and Guidotti*, 327
- Conway, J. G., Kauffman, F. C., Tsukada, T., and Thurman, R. G.** Glucuronidation of 7-Hydroxycoumarin in Periportal and Pericentral Regions of the Liver Lobule, 487
- Cragoe, E. J., Jr.** See *Vigne, Frelin, and Lazdunski*, 131

D

- Dahlberg, Erik, Thalén, Arne, Brattsand, Ralph, Gustafsson, Jan-Åke, Johansson, Ulf, Roemke, Karin, and Saartok, Tönu.** Correlation between Chemical Structure, Receptor Binding, and Biological Activity of Some Novel, Highly Active, 16 α ,17 α -Acetal-Substituted Glucocorticoids, 70
- Dahlberg, William.** See *Kufe, Weichselbaum, Egan, and Fram*, 322
- Dahlin, David C.** See *Rosen, Rauckman, Ellington, Christie, and Nelson*, 151
- Daly, J. W.**
See *Souccar, Varanda, and Albuquerque*, 384
See *Souccar, Varanda, Aronstam, and Albuquerque*, 395
- Dibartolomeis, Michael J., and Jefcoate, Colin R.** The Interrelationship of Polycyclic Hydrocarbon Metabolism and Steroidogenesis in Primary Cultures of Bovine Adrenal Cortical Cells, 476
- Drissi, R.** See *Castanas, Giraud, Audigier, Boudouresque, Conte-Devolx, and Oliver*, 38
- Drummond, Alan H.**
Bushfield, Mark, and Macphee, Colin H. Thyrotropin-Releasing Hormone-Stimulated [³H]Inositol Metabolism in GH₃ Pituitary Tumor Cells: Studies with Lithium, 201

Drummond, Alan H.—Continued

See *Macphee*, 193

Dumont, Jacques E. See *Miot, Erneux, and Wells*, 261

E

Egan, E. Michael. See *Kufe, Weichselbaum, Dahlberg, and Fram*, 322
Ehlert, Frederick J., and Jenden, Donald J. Comparison of the Muscarinic Receptor Binding Activity of Some Tertiary Amines and Their Quaternary Ammonium Analogues, 46

Elduson, Samuel. See *Buckman and Sutphin*, 165

Eldefrawi, A. T. See *El-Fakahany, Murphy, Aguayo, Trigg, Albuquerque, and Eldefrawi*, 369

Eldefrawi, M. E. See *El-Fakahany, Eldefrawi, Murphy, Aguayo, Trigg, and Albuquerque*, 369

El-Fakahany, E. E., Eldefrawi, A. T., Murphy, D. L., Aguayo, L. G., Trigg, D. J., Albuquerque, E. X., and Eldefrawi, M. E. Interactions of Phencyclidine with Crayfish Muscle Membranes: Sensitivity to Calcium Channel Antagonists and Other Drugs, 369

Ellestad, G. A. See *Fesik, Armitage, and McGahren*, 275, 281

Ellington, Sharon P. See *Rosen, Rauckman, Dahlin, Christie, and Nelson*, 151

Erneux, Christophe. See *Miot, Wells, and Dumont*, 261

F

Fain, John N. See *Mohell and Wallace*, 64

Fesik, S. W.

Armitage, I. M., Ellestad, G. A., and McGahren, W. J. Nuclear Magnetic Resonance Studies on the Antibiotic Avoparcin: Conformational Properties in Relation to Antibacterial Activity, 275

Armitage, I. M., Ellestad, G. A., and McGahren, W. J. Nuclear Magnetic Resonance Studies on the Interaction of Avoparcin with Model Receptors of Bacterial Cell Walls, 281

Fischer, Paul H., and Phillips, Anthony W. Antagonism of Feedback Inhibition: Stimulation of the Phosphorylation of Thymidine and 5-Iodo-2'-deoxyuridine by 5-Iodo-5'-amino-2',5'-dideoxyuridine, 446

Fram, Robert J. See *Kufe, Weichselbaum, Egan, and Dahlberg*, 322

Frelin, C. See *Vigne, Cragoe, and Lazdunski*, 131

G

George, John W. See *Pohl, Schulick, and Highet*, 318

Giraud, P. See *Castanas, Audigier, Drissi, Boudouresque, Conte-Devolx, and Oliver*, 38

Goldman, Mark E., and Kebabian, John W. Apomorphine Enantiomers: Interactions with D-1 and D-2 Dopamine Receptors, 18

Goldstein, Avram

and **James, Iain F.** Site-Directed Alkylation of Multiple Opioid Receptors. II. Pharmacological Selectivity, 343

See *James*, 337

Goldstein, Joyce A., and Linko, Patricia. Differential Induction of Two 2,3,7,8-Tetrachlorodibenzo-*p*-dioxin-Inducible Forms of Cytochrome P-450 in Extrahepatic versus Hepatic Tissues, 185

Gould, Robert J., Murphy, Kenneth M. M., and Snyder, Solomon H. Tissue Heterogeneity of Calcium Channel Antagonist Binding Sites Labeled by [³H]Nitrendipine, 235

Gresh, Nohad, and Pullman, Bernard. A Theoretical Study of the Nonintercalative Binding of Berenil and Stilbamidine to Double-Stranded (dA-dT)_n Oligomers, 452

Groh, Gordon I. See *Harris, Baxter, and Hitzemann*, 410

Guidotti, Alessandro. See *Saiani, Kageyama, and Conti-Tronconi*, 327

Gustafsson, Jan-Åke. See *Dahlberg, Thalén, Brattsand, Johansson, Roempke, and Saartok*, 70

H

Hakala, Maire T. See *Berger*, 303

Hankin, Hilda. See *Maragoudakis, Wasvary, and Gargiulo*, 425

Hanstock, Christopher C. See *Lown, Bradley, and Scraba*, 178

Harris, R. Adron

Baxter, Diane M., Mitchell, Mark A., and Hitzemann, Robert J. Physical Properties and Lipid Composition of Brain Membranes from Ethanol Tolerant-Dependent Mice, 401

Groh, Gordon I., Baxter, Diane M., and Hitzemann, Robert J. Gangliosides Enhance the Membrane Actions of Ethanol and Pentobarbital, 410

Henry, Jean-Pierre. See *Scherman*, 113

Highet, Robert J. See *Pohl, Schulick, and George*, 318

Hiller, Jacob M., Angel, Lloyd M., and Simon, Eric J. Characterization of the Selective Inhibition of the Delta Subclass of Opioid Binding Sites by Alcohols, 249

Hitzemann, Robert J.

See *Harris, Baxter, and Mitchell*, 401

See *Harris, Groh, and Baxter*, 410

Holford, Nicholas H. G. See *Rosenbaum, Richards, Aman, and Sadée*, 242

Honoré, Bent, and Brodersen, Rolf. Albumin Binding of Anti-Inflammatory Drugs: Utility of a Site-Oriented versus a Stoichiometric Analysis, 137

Hoyer, Daniel, Reynolds, Elwood E., and Molinoff, Perry B. Agonist-Induced Changes in the Properties of Beta-Adrenergic Receptors in Intact S49 Lymphoma Cells: Time-Dependent Changes in the Affinity of the Receptors for Agonists, 209

I

Ikeda, Stephen R. See *Akaike, Brookes, Pascuzzo, Rickett, and Albuquerque*, 102

J

James, Iain F.

and **Goldstein, Avram.** Site-Directed Alkylation of Multiple Opioid Receptors. I. Binding Selectivity, 337

See *Goldstein*, 343

Jefcoate, Colin R. See *Dibartolomeis*, 476

Jekunen, Antti, and Vilpo, Juhani A. 5-Methyl-2'-Deoxycytidine: Metabolism and Effects on Cell Lethality Studied with Human Leukemic Cells *in Vitro*, 431

Jenden, Donald J. See *Ehlert*, 46

Johansson, Ulf. See *Dahlberg, Thalén, Brattsand, Gustafsson, Roempke, and Saartok*, 70

K

Kageyama, Hiroyasu. See *Saiani, Conti-Tronconi, and Guidotti*, 327

Kauffman, Frederick C.

See *Belinsky, Matsumura, and Thurman*, 158

See *Conway, Tsukada, and Thurman*, 487

Kebabian, John W. See *Goldman*, 18

Koop, Dennis R., and Coon, Minor J. Purification of Liver Microsomal Cytochrome P-450 Isozymes 3a and 6 from Imidazole-Treated Rabbits: Evidence for the Identity of Isozyme 3a with the Form Obtained by Ethanol Treatment, 494

Kuenzel, Elizabeth A. See *Willow and Catterall*, 228

Kufe, Donald W., Weichselbaum, Ralph, Egan, E. Michael, Dahlberg, William, and Fram, Robert J. Lethal Effects of 1-β-D-Arabinofuranosylcytosine Incorporation into Deoxyribonucleic Acid during Ultraviolet Repair, 322

L

Langry, Kevin C. See *Ortiz de Montellano and Stearns*, 310

Lazdunski, M. See *Vigne, Frelin, and Cragoe*, 131

Liang, T. See *Cascieri, Bull, Mumford, Patchett, and Thornberry*, 287

Linko, Patricia. See *Goldstein*, 185

Lown, J. William, Hanstock, Christopher C., Bradley, Roger D., and Scraba, Douglas G. Interactions of the Antitumor

Agents Mitoxantrone and Bisantrene with Deoxyribonucleic Acids Studied by Electron Microscopy, 178

M

- Macphee, Colin H.**
and **Drummond, Alan H.** Thyrotropin-Releasing Hormone Stimulates Rapid Breakdown of Phosphatidylinositol 4,5-bisphosphate and Phosphatidylinositol 4-phosphate in GH₃ Pituitary Tumor Cells, 193
See *Drummond and Bushfield*, 201
- Mahan, Lawrence C.** See *Motulsky*, 1
- Majewska, Maria Dorota, and Chuang, De-Maw.** Modulation by Calcium of γ -Aminobutyric Acid (GABA) Binding to GABA_A and GABA_B Recognition Sites in Rat Brain: Involvement of Different Mechanisms, 352
- Maleque, Mohammed A.** See *Pascuzzo, Akaike, Shaw, Aronstam, Rickett, and Albuquerque*, 86
- Maragoudakis, Michael E., Wasvary, James, Hankin, Hilda, and Gargiulo, Paul.** Human Placenta Aldose Reductase: Forms Sensitive and Insensitive to Inhibition by Alrestatin, 425
- Matsumura, Takakatsu.** See *Belinsky, Kauffman, and Thurman*, 158
- Matubayashi, Norihiro.** See *Mori and Ueda*, 123
- McGahren, W. J.** See *Fesik, Armitage, and Ellestad*, 275, 281
- McLaughlin, James T.** See *Oswald and Bamberger*, 360
- Mellon, William S.**
Dye-Ligand Interactions with 1,25-Dihydroxyvitamin D₃-Receptor Complexes from Chicken Intestine, 79
Specificity of Dye-Ligand Interaction with the Polynucleotide Binding Domain of 1,25-Dihydroxyvitamin D₃-Receptor Complexes of Chicken Intestinal Cytosol, 86
- Mieyal, John J.** See *Starke and Blisard*, 467
- Minneman, Kenneth P., and Abel, Peter W.** "Spare" Alpha₁-Adrenergic Receptors and the Potency of Agonists in Rat Vas Deferens, 56
- Miot, Françoise, Erneux, Christophe, Wells, Jack N., and Dumont, Jacques E.** The Effects of Alkylated Xanthines on Cyclic AMP Accumulation in Dog Thyroid Slices Exposed to Carbamylcholine, 261
- Mitchell, Mark A.** See *Harris, Baxter, and Hitzemann*, 401
- Mohell, Nina, Wallace, Michael, and Fain, John N.** Alpha₁-Adrenergic Stimulation of Phosphatidylinositol Turnover and Respiration of Brown Fat Cells, 64
- Molinoff, Perry B.** See *Hoyer and Reynolds*, 209
- Momparler, Louise F.** See *Momparler, Rossi, Bouchard, Vaccaro, and Bartolucci*, 436
- Momparler, Richard L., Rossi, Mosé, Bouchard, Jacques, Vaccaro, Carlo, Momparler, Louise F., and Bartolucci, Simonetta.** Kinetic Interaction of 5-AZA-2'-Deoxycytidine-5'-Monophosphate and Its 5'-Triphosphate with Deoxycytidylate Deaminase, 436
- Mori, Takahiko, Matubayashi, Norihiro, and Ueda, Issaku.** Membrane Expansion and Inhalation Anesthetics: Mean Excess Volume Hypothesis, 123
- Motulsky, Harvey J., and Mahan, Lawrence C.** The Kinetics of Competitive Radioligand Binding Predicted by the Law of Mass Action, 1
- Mumford, R. A.** See *Cascieri, Bull, Patchett, Thornberry, and Liang*, 287
- Murphy, D. L.** See *El-Fakahany, Eldefrawi, Aguayo, Trigg, Albuquerque, and Eldefrawi*, 369
- Murphy, Kenneth M. M.** See *Gould and Snyder*, 235

N

- Neff, N. H.** See *Wojcik*, 24
- Nelson, Sidney D.** See *Rosen, Rauckman, Ellington, Dahlin, and Christie*, 151
- Nishimura, Stephen L., Recht, Lawrence D., and Pasternak,**

Gavril W. Biochemical Characterization of High-Affinity ³H-Opioid Binding: Further Evidence for Mu₁ Sites, 29

O

- Ohizumi, Yasushi.** See *Tatsumi and Takahashi*, 379
- Oliver, C.** See *Castanas, Giraud, Audigier, Drissi, Boudouresque, and Conte-Devolx*, 38
- Ortiz de Montellano, Paul R., Stearns, Ralph A., and Langry, Kevin C.** The Allylisopropylacetamide and Novonal Prosthetic Heme Adducts, 310
- Oswald, Robert E., Bamberger, Michelle J., and McLaughlin, James T.** Mechanism of Phencyclidine Binding to the Acetylcholine Receptor from *Torpedo* Electropaque, 360

P

- Pascuzzo, Gary J.**
Akaike, Akinori, Maleque, Mohammed A., Shaw, Kai-Ping, Aronstam, Robert S., Rickett, Daniel L., and Albuquerque, Edson X. The Nature of the Interactions of Pyridostigmine with the Nicotinic Acetylcholine Receptor-Ionic Channel Complex. I. Agonist, Desensitizing, and Binding Properties, 92
See *Akaike, Ikeda, Brookes, Rickett, and Albuquerque*, 102
- Pasternak, Gavril W.** See *Nishimura and Recht*, 29
- Patchett, A. A.** See *Cascieri, Bull, Mumford, Thornberry, and Liang*, 287
- Pedone, Carolyn.** See *Barovsky and Brooker*, 256
- Phillips, Anthony W.** See *Fischer*, 446
- Pohl, Lance R., Schulick, Richard D., Highet, Robert J., and George, John W.** Reductive-Oxygenation Mechanism of Metabolism of Carbon Tetrachloride to Phosgene by Cytochrome P-450, 318
- Postma, Sidney W., and Catterall, William A.** Inhibition of Binding of [³H]Batrachotoxinin A 20 α -Benzoate to Sodium Channels by Local Anesthetics, 219
- Prusoff, William H.** See *Chen and Woods*, 441
- Pullman, Bernard.** See *Gresh*, 452

R

- Rauckman, Elmer J.** See *Rosen, Ellington, Dahlin, Christie, and Nelson*, 151
- Recht, Lawrence W.** See *Nishimura and Pasternak*, 29
- Reynolds, Elwood E.** See *Hoyer and Molinoff*, 209
- Richards, Mark L.** See *Rosenbaum, Holford, Aman, and Sadée*, 242
- Rickett, Daniel L.** See *Pascuzzo, Akaike, Maleque, Shaw, Aronstam, and Albuquerque*, 92
- Roempke, Karin.** See *Dahlberg, Thalén, Brattsand, Gustafsson, Johansson, and Saartok*, 70
- Rogers, Deloris C.** See *Conn and Seay*, 51
- Rosen, Gerald M., Rauckman, Elmer J., Ellington, Sharon P., Dahlin, David C., Christie, James L., and Nelson, Sidney D.** Reduction and Glutathione Conjugation Reactions of *N*-Acetyl-p-Benzoquinone Imine and Two Dimethylated Analogues, 151
- Rosenbaum, Jan S., Holford, Nicholas H. G., Richards, Mark L., Aman, Rashid A., and Sadée, Wolfgang.** Discrimination of Three Types of Opioid Binding Sites in Rat Brain *in Vivo*, 242
- Rossi, Mosé.** See *Momparler, Bouchard, Vaccaro, Momparler, and Bartolucci*, 436

S

- Saartok, Tõnu.** See *Dahlberg, Thalén, Brattsand, Gustafsson, Johansson, and Roempke*, 70
- Sadée, Wolfgang.** See *Rosenbaum, Holford, Richards, and Aman*, 242
- Saiani, Laura, Kageyama, Hiroyasu, Conti-Tronconi, Bianca M., and Guidotti, Alessandro.** Purification and Characteriza-

- tion of a Bungarotoxin Polypeptide Which Blocks Nicotinic Receptor Function in Primary Culture of Adrenal Chromaffin Cells, 327
- Scherman, Daniel, and Henry, Jean-Pierre.** Reserpine Binding to Bovine Chromaffin Granule Membranes: Characterization and Comparison with Dihydropyridine Binding, 113
- Schulick, Richard D.** See *Pohl, Highet, and George*, 318
- Scraba, Douglas G.** See *Lown, Hanstock, and Bradley*, 178
- Seay, Sallie G.** See *Conn and Rogers*, 51
- Seeman, Philip.** See *Wreggett*, 10
- Shaw, Kai-Ping.** See *Pascuzzo, Akaiki, Maleque, Aronstam, Rickett, and Albuquerque*, 86
- Silver, Paul J., and Stull, James T.** Phosphorylation of Myosin Light Chain and Phosphorylase in Tracheal Smooth Muscle in Response to KCl and Carbachol, 267
- Simon, Eric J.** See *Hiller and Angel*, 249
- Slieker, L. J., and Benkovic, S. J.** Inhibition of HKSV28 Cell Growth by 5,11-Methenyltetrahydrohomofolate, 294
- Snyder, Solomon H.** See *Gould and Murphy*, 235
- Souccar, C.**
- Varanda, W. A., Aronstam, R. S., Daly, J. W., and Albuquerque, E. X.** Interactions of Gephyrotoxin with the Acetylcholine Receptor-Ionic Channel Complex. II. Enhancement of Desensitization, 395
- Varanda, W. A., Daly, J. W., and Albuquerque, E. X.** Interactions of Gephyrotoxin with the Acetylcholine Receptor-Ionic Channel Complex. I. Blockade of the Ionic Channel, 384
- Spector, Sydney.** See *Wang and Taniguchi*, 349
- Starke, David W., Blisard, Karen S., and Mieyal, John J.** Substrate Specificity of the Monooxygenase Activity of Hemoglobin, 467
- Stearns, Ralph A.** See *Ortiz de Montellano and Langry*, 310
- Stull, James T.** See *Silver*, 267
- Sutphin, Mary S.** See *Buckman and Eiduson*, 165
- T**
- Takahashi, Masami.** See *Tatsumi and Ohizumi*, 379
- Taniguchi, Takashi.** See *Wang and Spector*, 349
- Tatsumi, Masahiro, Takahashi, Masami, and Ohizumi, Yasushi.** Mechanism of Palytoxin-Induced [³H]Norepinephrine Release from a Rat Pheochromocytoma Cell Line, 379
- Thalén, Arne.** See *Dahlberg, Brattsand, Gustafsson, Johansson, Roempke, and Saartok*, 70
- Thornberry, N. A.** See *Cascieri, Bull, Mumford, Patchett, and Liang*, 287
- Thurman, Ronald G.**
- See *Belinsky, Matsumura, and Kauffman*, 158
- See *Conway, Kauffman, and Tsukada*, 487
- Triggle, D. J.** See *El-Fakahani, Eldefrawi, Murphy, Aguayo, Albuquerque, and Eldefrawi*, 369
- Tsukada, T.** See *Conway, Kauffman, and Thurman*, 487
- U**
- Ueda, Issaku.** See *Mori and Matubayashi*, 123
- V**
- Vaccaro, Carlo.** See *Momparler, Rossi, Bouchard, Momparler, and Bartolucci*, 436
- Varanda, W. A.**
- See *Souccar, Aronstam, Daly, and Albuquerque*, 395
- See *Souccar, Daly, and Albuquerque*, 384
- Vigne, P., Frelin, C., Cragoe, E. J., Jr., and Lazdunski, M.** Structure-Activity Relationships of Amiloride and Certain of Its Analogues in Relation to the Blockade of the Na⁺/H⁺ Exchange System, 131
- Vilpo, Juhani A.** See *Jekunen*, 431
- W**
- Wallace, Michael.** See *Mohell and Fain*, 64
- Wang, James K. T., Taniguchi, Takashi, and Spector, Sydney.** Structural Requirements for the Binding of Benzodiazepines to Their Peripheral-Type Sites, 349
- Washtien, Wendy L.** Increased Levels of Thymidylate Synthetase in Cells Exposed to 5-Fluorouracil, 171
- Wasvary, James.** See *Maragoudakis, Hankin, and Gargiulo*, 425
- Weichselbaum, Ralph.** See *Kufe, Egan, Dahlberg, and Fram*, 322
- Wells, Jack N.** See *Miot, Erneux, and Dumont*, 261
- Willow, Max, Kuenzel, Elizabeth A., and Catterall, William A.** Inhibition of Voltage-Sensitive Sodium Channels in Neuroblastoma Cells and Synaptosomes by the Anticonvulsant Drugs Diphenylhydantoin and Carbamazepine, 228
- Wojcik, W. J., and Neff, N. H.** γ -Aminobutyric Acid B Receptors Are Negatively Coupled to Adenylate Cyclase in Brain, and in the Cerebellum These Receptors May Be Associated with Granule Cells, 24
- Woods, Kathleen L.** See *Chen and Prusoff*, 441
- Wreggett, Keith A., and Seeman, Philip.** Agonist High- and Low-Affinity States of the D₂-Dopamine Receptor in Calf Brain: Partial Conversion by Guanine Nucleotide, 10

Notice to Authors Wishing to Submit Manuscripts to

Journal of Pharmacology and Experimental Therapeutics

Molecular Pharmacology

Drug Metabolism and Disposition

The expenses associated with the review of manuscripts submitted to those ASPET-sponsored journals that are devoted to publishing original research articles have escalated dramatically in recent years because of ever-increasing costs of postage, supplies, and other office expenses, and the growing number of manuscripts submitted for publication. In order to continue to offer authors the opportunity to publish their original research in our critically reviewed, well-edited, and widely respected journals, it has become necessary for ASPET to follow the example of several other scientific societies which have instituted a uniform manuscript handling fee for each of its journals that publishes original research reports. Therefore, all manuscripts received in the editorial office on or after July 1, 1983, must be accompanied either by a check for \$30.00 (in U. S. funds payable to ASPET) or by a validated purchase order from the authors' institution. The review process for submitted manuscripts will be delayed until the manuscript handling fee or purchase order is received in the appropriate Editor's office. We regret the necessity of instituting a manuscript handling fee. The Board of Publications Trustees has concluded, however, that this charge represents the fairest and most appropriate manner to defray the costs related to the review of submitted manuscripts. If submission of the manuscript handling fee entails a personal financial hardship to the author(s), the fee will be waived. In that event, the author(s) should submit a request for waiver of the fee when the manuscript is submitted.

INSTRUCTIONS TO AUTHORS

Molecular Pharmacology will publish the results of investigations that contribute significant new information on drug action or selective toxicity at the molecular level. The term "drug" is defined broadly to include chemicals that selectively modify biological function.

Suitable papers are those that describe applications of the methods of biochemistry, biophysics, genetics, and molecular biology to problems in pharmacology or toxicology. Also suitable are reports of fundamental investigations which, although not concerned directly with drugs, nevertheless provide an immediate basis for further study of the molecular mechanism of drug action. Observations of phenomena that shed no light upon underlying molecular interactions are not appropriate for publication. Comparative studies, such as those involving drug-receptor or drug-enzyme interactions that already have been well characterized in other types of cells or tissues, also are inappropriate for publication unless they contribute significant new insight into mechanisms.

Specific areas of interest include: stereochemical, electronic, and other parameters of drug architecture; conformational analysis of receptors and their function; drug-enzyme and other interactions between drugs and macromolecules; drug effects upon gene replication and transcription and on protein synthesis; mechanism of action of antibiotics and other growth-inhibitory drugs; induction by drugs of changes in macromolecular structure or allosteric transitions; drug-induced alterations in metabolic pathways; effects of hormones and other drugs on cellular regulatory mechanisms; chemical mutagenesis, carcinogenesis, and teratogenesis; pharmacogenetics, idiosyncrasies, and drug allergies; selective toxicity in a single organism or in different species; drug actions on properties and functions of membranes; mechanisms of drug metabolism; distribution and transport of drug molecules between biological compartments.

Page charges. Authors will be billed at the rate of \$30.00 per page after the paper has been published. It is expected that the page charge will be paid if funds are available for that purpose from the author's institution or from the sponsor of this research. Payment of the charge is not a condition for publication. In case of personal financial hardship, page charges will be waived. Neither the editors nor the reviewers will have knowledge as to who has paid the charge, and this payment always will be considered entirely voluntary.

Submission of manuscript. Manuscripts are published in English only and should be sent to Dr. Joel Hardman, Editor, *Molecular Pharmacology*, Department of Pharmacology, Vanderbilt University Medical Center, Nashville, Tennessee 37232, U. S. A.

The expenses associated with the review of manuscripts submitted to *Molecular Pharmacology* and other ASPET-sponsored journals that are devoted to publishing original research articles have escalated dramatically in recent years because of ever-increasing costs of postage, supplies, and other office expenses, and the growing number of manuscripts submitted for publication. Thus, it has become necessary for ASPET to follow the example of several other scientific societies which have instituted uniform manuscript handling fees. Therefore, all manuscripts must be accompanied either by a check for \$30 (in U. S. funds payable to ASPET) or by a validated purchase order from the authors' institution. The review process for submitted manuscripts will be delayed until the manuscript handling fee or purchase order is received in the Editor's office. If submission of the manuscript handling fee entails a personal financial hardship to the author(s), the fee will be waived. In that event, the author(s) should submit a request for waiver of the fee when the manuscript is submitted.

Manuscripts should be typewritten double-spaced with ample margins on one side of the paper, 8½ × 11 inches (ca. 215 × 280 mm). Submit four complete copies of the manuscript and four copies of each figure, plus one original drawing or photograph of each figure. Each half-tone figure requires four original drawings or photographs. All pages should be numbered consecutively beginning with the title page. Limit your reference listings to the minimal number required to document the manuscript adequately. In most instances 30 references or fewer should suffice.

Under usual circumstances reviewers will be instructed to return only their comments to the editorial office and to destroy manuscripts after a final decision on their acceptability has been made.

Original figures and single copies of manuscripts not accepted for publication will be returned to the authors upon request.

It is understood that the manuscripts and the results they contain will not have been published previously and are not being submitted elsewhere. Manuscripts are accepted for review with the understanding that all persons listed as authors have given their approval for the submission of the paper; further, that any person cited as a source of personal communications has approved such citation. Written authorization may be required at the Editor's discretion. Articles and any other material published in *Molecular Pharmacology* represent the opinions of the author(s) and should not be construed to reflect the opinions of the Editor(s) and the Publisher. If and when a manuscript is published, it will become the sole property of the Journal.

Authors submitting a manuscript do so on the understanding that if it is accepted for publication, copyright in the article, including the right to reproduce the article in all forms and media, shall be assigned exclusively to the Society for Pharmacology and Experimental Therapeutics. No reasonable request by the author for permission to reproduce any of his or her contributions to the journal will be refused.

Organization and style of manuscripts. The policy of the Journal is to allow authors maximum freedom in organizing and presenting their material, and in expressing their ideas, provided only that clarity and conciseness are achieved. For most manuscripts, the most suitable format is: (1) Summary, (2) Introduction, (3) Materials and Methods, (4) Results, and (5) Discussion.

Certain conventions must be observed. Chemical and mathematical formulas and abbreviations should follow the *Instructions to Authors of the Journal of Biological Chemistry* (Vol. 258, pp. 1-11, January 10, 1983). Drugs must be referred to by their generic or chemical names throughout the text, but may be identified by trade name in parentheses or a footnote. The systematic name and number given by the Commission on Enzymes of the International Union of Biochemistry should be included for each enzyme of importance in a paper, at the point in the Summary or Introduction where the enzyme is first mentioned. The use of abbreviations should be minimized and abbreviations avoided in the Summary. All essential abbreviations should be defined in a single footnote when first introduced. Abbreviations of journal names should conform to the style of *Biological Abstracts*. References to papers that

have been accepted for publication, but have not appeared, should be cited like other references with the abbreviated name of the journal followed by the words "in press." Copies of such papers should be sent whenever the findings described in them have a direct bearing on the paper being submitted for publication. "Personal Communications" and "Unpublished Observations" should be cited in footnotes to the text and should not be included in the reference list.

A manuscript should include the following, in the order listed: (1) Title. Numbered footnotes to the title should be avoided; acknowledgment of financial support should be given in an unnumbered footnote to the title. (2) Names of authors, their laboratory and institution. (3) A running title, not exceeding 60 characters and spaces. (4) Summary. (5) Text. Footnotes should be referred to by superscript numbers and references by numbers in parentheses. (6) References, numbered according to order of citation in the text, including title and complete pagination. Examples: 1. Goren, J. H., L. G. Baue, and W. Vale. Forces and structural limitations of binding of thyrotropin-releasing receptor: the pyroglutamic acid moiety. *Mol. Pharmacol.* 13:606-614 (1977). 2. Sandler, M. Variations in monoamine oxidase activity in some human disease states, in *Monoamine Oxidase and Its Inhibition*. Ciba Foundation Symposium 39. Elsevier, Amsterdam, 327-340 (1976). (7). Footnotes, numbered according to order of appearance in the text. (8) Tables. (9) Figures. (10) Legends to figures. (11) Name and address of person to receive galley proof.

Tables. These should be numbered with arabic numerals and designed to fit the single-column width of the full-page width. Every table should have an explanatory title and sufficient experimental detail in a paragraph following the title to be intelligible without references to the text (unless the procedure is given in the Methods section, or under another table or figure). Footnotes to tables should

appear beneath the tables themselves and should be designated by lower-case italic superscript letters, *a*, *b*, *c*, etc.

Figures. These should be numbered with arabic numerals. Each of the four manuscript copies should contain all of the figures. Only the original set need be of quality suitable for reproduction except in the case of half-tones, which require four sets of photographs or original drawings. These should be unmounted glossy photographs (or original India-ink drawings). Usually figures will be reduced to one column width (85 mm) and all numbers *after* such reduction should be at least 1.5 mm high. The figures must be ready, in all respects, for direct reproduction: no lettering or other art work will be done by the publisher. If symbols are not explained on the face of the figure, only standard characters, of which the printer has type, may be used (\times , \circ , \bullet , \square , \blacksquare , \triangle , \blacktriangle , \odot). The back of each photograph should bear its number, and the legend TOP at the appropriate edge. The list of legends for the figures should give captions and sufficient experimental detail, as required for tables.

Galley proof. The cost of all changes on galley proof, other than printer's errors, will be charged to authors. The Editors are very much interested in having accepted contributions appear in the earliest possible issue of the Journal, and therefore request that galley proof be returned within 24 hours after its receipt. In exceptional cases, a "Note added in proof" may be attached and will be published if the Editor approves.

Reprints and page charges. An order form for reprints as well as information on the estimation of page charges will be mailed with galley proof. Please direct questions on reprints, page charges, or other business matters to Kay Croker, Acting Executive Officer, American Society for Pharmacology and Experimental Therapeutics, 9650 Rockville Pike, Bethesda, Md. 20814. Telephone (301)530-7060.